Biogen (BIIB) option IV into Clinical Trials on Alzheimer's Congress

Biogen (NASDAQ: BIIB) December weekly option implied volatility is at 55, December is at 51; compared to its 52-week range of 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• Backblaze (BLZE) call put ratio 12.9 calls to 1 put with a focus on July 12.50 calls as share price up 40%
• Genco Shipping & Trading Limited (GNK) 8400 contracts of August 30 calls trade, share price up 5.5%